Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 16/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.34 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.34 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.34 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.34 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.34 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.34 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17261132 | 1.00 | AVPR1B (0.45) | AVPR1BCYP3A4MEN1MAPTKMT2A | |
| SCHEMBL1589499 | 0.89 | AVPR1B (0.57) | AVPR1B | |
| SCHEMBL17261046 | 0.86 | AVPR1B (0.58) | AVPR1BCYP3A4MEN1MAPTKMT2A | |
| SCHEMBL1875220 | 0.86 | AVPR1B (0.58) | AVPR1BCYP3A4MEN1MAPTKMT2A | |
| SCHEMBL15279956 | 0.85 | AVPR1B (0.41) | AVPR1BCYP3A4SLC22A12 | |
| SCHEMBL1589612 | 0.83 | AVPR1B (0.39) | AVPR1BCYP3A4KMT2A | |
| SCHEMBL1876402 | 0.81 | AVPR1B (0.48) | AVPR1BCYP3A4MAPT | |
| SCHEMBL1880680 | 0.81 | AVPR1B (0.46) | AVPR1BCYP3A4MAPTKMT2A | |
| SCHEMBL1871648 | 0.80 | AVPR1B (0.45) | AVPR1BCYP3A4MAPT | |
| SCHEMBL1589255 | 0.80 | KMT2A (0.40) | AVPR1BMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143023-B1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | ABBVIE DEUTSCHLAND (DE) | 2018-04-11 | — | — | EP | disclosed |
| EP-3143023-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-9527856-B2 | Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-12-27 | — | — | US | disclosed |
| US-9434713-B2 | 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-09-06 | — | — | US | disclosed |
| US-20150344489-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-03 | — | — | US | disclosed |
| WO-2015173392-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-11-19 | — | — | WO | disclosed |
| US-20140194440-A1 | 5,6-DISUBSTITUTED OXINDOLE-DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-10 | — | — | US | disclosed |
| EP-2231644-B1 | 5,6-Disubstituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases | ABBVIE DEUTSCHLAND (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-8546401-B2 | 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2623504-A1 | 5,6-Disubstituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases | Abbott GmbH & Co. KG (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-20110092513-A1 | 5,6-DISUBSTITUTED OXINDOLE-DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG | 2011-04-21 | — | — | US | disclosed |
| EP-2231644-A2 | 5,6-DISUBSTITUTED OXINDOLE-DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSINE-DEPENDENT DISEASES | Abbott GmbH & Co. KG (DE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009071690-A2 | 5,6-DISUBSTITUTED OXINDOLE-DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSINE-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092513-A1 | 5,6-DISUBSTITUTED OXINDOLE-DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 3678/4885MEN1 804/4885 |
| US-20150344489-A1 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 1412/4885MEN1 468/4885 |
| US-20140194440-A1 | 5,6-DISUBSTITUTED OXINDOLE-DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 3678/4885MEN1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.